Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based VP’ operating in the Biopharma space. If you think a VP’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Bruno Angelici
Executive VP of AstraZeneca
Bruno Angelici was appointed in 2007, current term until 2019. He was formerly Executive Vice President, Europe, Japan, Asia Pacific, Latin America, Middle East, and Africa of AstraZeneca Plc.
Follow Bruno Angelici:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
James Weatherall
VP, Data Science & AI, Research and Development of AstraZeneca
Jim Weatherall is Head of the Advanced Analytics Centre (AAC) at AstraZeneca, a department of approximately 30 clinical and health data scientists across three countries covering the disciplines of advanced statistics, scientific computing, and biomedical and health informatics. A particle physicist by training, Jim spent time as an academic researcher, before becoming a scientific software engineer consulting across a range of different industries, including the life sciences. He has had affiliate staff status at the University of Manchester since 2012, most recently being appointed as honorary reader at the University’s Health eResearch Centre. Jim and his team have introduced a number of innovations into the clinical research field, in areas such as data and text mining, data visualization, health technology evaluation, and clinical trial design.
Follow James Weatherall:
About AstraZeneca, University of Manchester: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Roger Pettett
VP, Informatics of Oxford Nanopore Technologies
Follow Roger Pettett:
About Oxford Nanopore Technologies: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Tim Cowper
VP, Finance of Oxford Nanopore Technologies
Tim Cowper is a Chartered Accountant and Operations specialist who has worked across a range of life science/healthcare companies in the UK and US, both private and public companies. These include Celltech, Vernalis/British Biotech, Bioventix and Sterilox. Qualified as an Accountant at Ernst & Young (Ernst & Whinney), Tim has directed companies in their financial management and also through transactions including M&A, reorganisations and IPOs. Tim joined Oxford Nanopore in a financial and operations role in 2012 and oversees the financial team as well as strategic supply chain operations. Tim is a keen sailor and was also Finance Director of Clipper Ventures.
Follow Tim Cowper:
About Oxford Nanopore Technologies: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Anthony Chow
VP IR of Juvenescence
Anthony Chow is a CFA Charter holder with broad experience as an investor. He commenced his career at ANZ Banking Group Ltd in Sydney, Australia where he worked as an analyst for four years in the corporate banking, leveraged finance and private equity teams. In 2007, Anthony moved to London to work for Jim Mellon at Burnbrae Group and Regent Pacific. Since joining, he was responsible research, direct investments, portfolio construction, risk management and facilitating trades in a wide range of financial instruments. He has worked closely with portfolio companies and respective coinvestors. He is currently the CEO of Burnbrae’s subsidiary Mann Bioinvest Limited and consultant to Juvenescence. He also sits on the board of The Diabetic Boot Company Limited, a medical device company. Anthony holds a Bachelor of Economics and Finance from The University of Sydney and a Post Graduate Diploma in Accounting from Macquarie University. He was awarded the CFA designation in 2010.
Follow Anthony Chow:
About Agronomics, Juvenescence: Juvenescence is a biotech company that develops therapies and products to modify aging and help people live longer.
Martin Ducker
Vice President of Juvenescence
Follow Martin Ducker:
About Juvenescence: Juvenescence is a biotech company that develops therapies and products to modify aging and help people live longer.
Martin Lachs
Vice President Global Project Management of ICON plc
Follow Martin Lachs:
About ICON plc: ICON is a global provider of outsourced drug development services to biopharma, medical device, biosimilar and generic organizations.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Simon Ashworth
VP, Head Safety and Pharmacovigilance of Autolus
Follow Simon Ashworth:
About Autolus, Takeda: Autolus is in T-cell programming and manufacturing technology.
Christopher Vann
Senior Vice President, Chief Operating Officer of Autolus
Christopher Vann leads commercial activities for Autolus. An industry veteran with 30 years’ experience in both development and business roles, he joined Autolus from Hoffmann-La Roche’s Swiss headquarters, where he was latterly responsible for leading the lung cancer commercial team and general management of the Tarceva brand. He has extensive experience of global lifecycle management of oncology products as well as implementing marketing strategy at a regional and national level. This includes launching several oncology, immunology and transplant products in countries such as China, Japan, Romania, Russia, South Africa, the UK and the USA. He gained his degree in toxicology and pharmacology from the School of Pharmacy, University of London.
Follow Christopher Vann:
About Autolus: Autolus is in T-cell programming and manufacturing technology.
Nicholas Lakin
Vice President, Advisory Services of Kinapse
Follow Nicholas Lakin:
About Kinapse: Kinapse provides advisory, capability building and operational services to the life sciences industries.
